Related Experiment Video
Updated: Jun 21, 2026
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Combination of viral oncolysis and tumor-specific immunity to control established tumors
Chi-Mu Chuang1, Archana Monie, Annie Wu
1Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA.
Purpose:
Advanced-stage cancers are extremely difficult to treat and rarely result in a cure. The application of oncolytic viruses is a potential strategy for controlling advanced-stage cancer because intratumoral (i.t.) injection of an oncolytic virus, such as vaccinia virus, results in tumor cell lysis and subsequent release of tumor antigens into the microenvironment. Furthermore, the viruses can serve as a vehicle for delivering genes of interest to cancer cells.
Experimental Design:
In the current study, we hypothesize that in tumor-bearing mice primed with DNA encoding an immunogenic foreign antigen, ovalbumin (OVA) followed by a boost with i.t. administration of vaccinia virus encoding the same foreign antigen, OVA, can generate enhanced antitumor effects through the combination of viral oncolysis and tumor-specific immunity.
Results:
We observed that tumor-bearing mice primed with OVA DNA and boosted with vaccinia encoding OVA (Vac-OVA) generated significant therapeutic antitumor effects as well as induced significant levels of OVA-specific CD8+ T cells in two different tumor models. Furthermore, treatment with Vac-OVA not only kills the tumor and stromal cells directly but also renders the tumor cells and surrounding stromal cells susceptible to OVA-specific CD8+ T-cell killing, resulting in enhanced antitumor therapeutic effects.
Conclusions:
Thus, the current study may provide a novel therapeutic strategy for the control of advanced-stage cancers.
Insights
This study shows that priming mice with ovalbumin (OVA) DNA followed by a vaccinia virus boost encoding OVA enhances antitumor effects. This combined approach leverages viral oncolysis and tumor-specific immunity for advanced cancer treatment.
Area of Science:
- Oncology
- Virology
- Immunology
Background:
- Advanced-stage cancers pose significant treatment challenges with limited cure rates.
- Oncolytic viruses, like vaccinia virus, offer a promising strategy for cancer control via tumor cell lysis and antigen release.
- Viruses can also function as delivery vehicles for therapeutic genes into cancer cells.
Purpose of the Study:
- To investigate if priming tumor-bearing mice with ovalbumin (OVA) DNA, followed by intratumoral vaccinia virus encoding OVA, enhances antitumor effects.
- To evaluate the combined impact of viral oncolysis and tumor-specific immunity.
Main Methods:
- Tumor-bearing mice were primed with DNA encoding the foreign antigen ovalbumin (OVA).
- Mice received a boost via intratumoral administration of vaccinia virus encoding OVA (Vac-OVA).
- Antitumor effects and OVA-specific CD8+ T cell responses were assessed in two tumor models.
Main Results:
- Priming with OVA DNA and boosting with Vac-OVA induced significant therapeutic antitumor effects.
- Significant levels of OVA-specific CD8+ T cells were generated in treated mice.
- Vac-OVA directly killed tumor and stromal cells and sensitized them to CD8+ T-cell mediated killing, enhancing therapeutic outcomes.
Conclusions:
- The combination of OVA DNA priming and Vac-OVA boosting presents a novel therapeutic strategy for advanced cancers.
- This approach effectively combines viral oncolysis with robust tumor-specific immunity.
Related Concept Videos
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...